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Abstract: Pancreatic -cells are sensitive to fluctuations in cholesterol content, which can damage 
the insulin secretion pathway, contributing to the aetiology of type 2 diabetes mellitus.   Cholesterol 
efflux to (apo)lipoproteins, via ATP binding cassette transporter A1 (ABCA1), can prevent 
intracellular cholesterol accumulation; in some peripheral cells, ABCA1-dependent efflux is 
enhanced by promotion of cholesterol trafficking to, and generation of Liver X receptor (LXR) 
ligands by, mitochondrial sterol 27-hydroxylase (Cyp27A1) and its redox partners, adrenodoxin 
(ADX) and adrenodoxin reductase (ADXR).  Despite this, the roles of mitochondrial cholesterol 
trafficking (steroidogenic acute regulatory protein [StAR] and 18kDa translocator protein [TSPO]) 
and metabolizing proteins in insulin-secreting cells remain wholly uncharacterised.  Here, we 
demonstrate an increase in pancreatic expression of Cyp27A1, ADXR, TSPO and LXR but not 
ADX or StAR, in obese (fa/fa) rodents compared with lean (Fa/?) controls. Overexpression of 
Cyp27A1 alone in BRIN-BD11 cells increased INS2 expression, without affecting lipid metabolism; 
however, after exposure to low density lipoprotein (LDL), cholesterol efflux to (apo)lipoprotein 
acceptors was enhanced in Cyp27A1-overexpressing cells.  Co-transfection of Cyp27A1, ADX and 
ADXR, at a ratio approximating that in pancreatic tissue, stimulated cholesterol efflux to apoA-I in 
both basal and cholesterol-loaded cells; insulin release was stimulated equally by all acceptors in 
cholesterol-loaded cells.  Thus, genetic obesity increases pancreatic expression of Cyp27A1, ADXR, 
TSPO, and LXR, while modulation of Cyp27A1 and its redox partners promotes cholesterol efflux 
from insulin-secreting cells to acceptor (apo)lipoproteins; this response may help guard against loss 








Abbreviations: ABCA1: ATP Binding Cassette (ABC) transporter A1; ABCG1/G4: ABC 
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The cluster of metabolic abnormalities found associated with type 2 diabetes mellitus (T2DM), 
including insulin resistance (IR), central obesity, high blood pressure and hypertriglyceridaemia, are 
associated with low levels of High Density Lipoprotein (HDL), and with dysfunctional HDL unable 
to exert the multiple protective mechanisms ascribed to this lipoprotein (reviewed by Vollenweider 
[1]).  Evidence links HDL with improved insulin sensitivity and glucose utilisation in skeletal muscle 
[2], and beneficial effects of HDL on insulin secretion have been reported in vivo [2-4] and in vitro 
in some [5] but not all studies [6-8].  High Density Lipoproteins can protect against -cell apoptosis, 
which can be triggered by an array of endoplasmic reticulum (ER) stressors [8-10]. Maintaining ER 
protein folding and trafficking is obviously critical in sustaining insulin secretion in the face of these 
challenges [9, 10].   
One key function of HDL is to modulate cholesterol homeostasis: cholesterol levels within -cells 
must remain within defined limits to maintain insulin secretion [11, 12], while the accumulation of 
free cholesterol within cells triggers ER stress [13, 14]. Apolipoprotein (apo) A-I, the major 
apolipoprotein in HDL, interacts with ATP binding cassette transporter A1 (ABCA1) to initiate 
cholesterol efflux [15], while ABCG1 transfers cholesterol and phospholipids to HDL [16, 17].  
Knockout studies in mice indicate that ABCG1 aids the enrichment of insulin secretory granules with 
cholesterol needed for their formation and trafficking to the plasma membrane [18], while ABCA1-
mediated cholesterol efflux is involved in their exocytosis [19-21].  The expression of both 
transporters is regulated by nuclear Liver X Receptors (LXR ), activated by endogenous 
oxysterol ligands that can be derived from the cholesterol biosynthetic pathway [22, 23], or the 
oxidative metabolism of cholesterol by sterol 27-hydroxylase (CYP27A1) within mitochondria [24, 
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25].  The latter pathway also provides an alternate route for elimination of excess cholesterol from 
cells in the periphery, via delivery of oxysterol to the liver for excretion [26].   
The rate-limiting step governing the activity of CYP27A1 and its redox partners, adrenodoxin 
(ADX) and adrenodoxin reductase (ADXR) [27, 28] is reported to be the delivery of cholesterol from 
the outer to the inner mitochondrial membrane [29, 30], a process facilitated by steroidogenic acute 
regulatory protein (StAR; STARD1) [31-33] and 18kDa translocator protein (TSPO) although the 
role of the latter remains controversial [34-38].  Overexpression and/or ligation of these proteins in 
macrophages can increase cholesterol efflux to (apo)lipoproteins, enhance ABCA1- and ABCG1 
dependent cholesterol efflux and reduce neutral lipid mass and inflammation, via a mechanism that 
involves activation and/or induction of LXR, and peroxisome proliferator activated receptor  
(PPAR) [39-42]. 
Despite the presence of CYP27A1 in human pancreatic -cells and islets [43], the function of 
mitochondrial cholesterol trafficking and metabolizing proteins in insulin-secreting cells remain 
entirely uncharacterised.  The aim of this study was to examine the impact of obesity on pancreatic 
expression of these mitochondrial proteins (Cyp27A1, ADX, ADXR, StARD1, TSPO, LXR) in the 
Zucker (fa/fa) rodent model of genetic obesity and their function in regulation of cholesterol efflux 
and insulin release in BRIN-BD11 insulinoma cells.   
Materials and Methods 
Materials 
Apolipoprotein A-I and HDL were purchased from Athens Research and Technology (Georgia, 
USA). All other materials were from UK companies, or UK suppliers for the companies 
indicated.  Radiochemicals were purchased from Perkin Elmer, Tri-Fast from PeqLab and cDNA 
synthesis kits from Bioline.  Rabbit monoclonal antibodies to Cyp27A1, ADX and LXR, and 
polyclonal antibodies to TSPO, ADXR and ABCA1 were purchased from AbCAM; rabbit 
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polyclonal antibody to StarD1 was from Santa Cruz.  Sodium pentobarbital was supplied by J.M. 
Loveridge plc, (Southampton), tissue culture reagents from Lonza, and sterile tissue culture plastics 
from Greiner. The clones for Cyp27A1, ADX and ADXR (pCMV) were from Origene.com via 
Cambridge Biosciences. Complete™ protease inhibitor cocktail was purchased from Roche, and 
chemicals, TLC plates and solvents from Sigma Aldrich.  
Experimental animals 
Heterozygous Zucker rats (Fa/fa) were supplied by Harlan Laboratories (Bicester, UK) and a 
breeding colony established.  Zucker rats were maintained in group (n=3) cages on sawdust bedding, 
on a 14h-light/10h-dark cycle with standard chow and water provided ad libitum.  Male lean 
(Fa/?; n=9) and obese (fa/fa; n=5) rats were terminally anaesthetized at four months, using 
pentobarbital sodium (100mg kg
-1
, I.P.).   Body weight was measured prior to commencement of 
study then weekly thereafter.  Blood was collected by cardiac puncture, and plasma levels of glucose 
and lipids determined, as described [44]; levels of serum insulin were determined using an ELISA 
supplied by Millipore.  Principles of laboratory animal care (NIHA publication no. 85-23, revised 
1985 (http://grants1.nih.gov/grants/olaw/references/phspol.htm) were followed.   The study was 
approved by the institution’s Animal Ethics and Welfare Committee, and procedures performed 
according to the UK Animals (Scientific Procedures) Act, 1986, and tissues harvested for multiple 
studies to reduce usage. 
Preparation of tissue samples 
Samples (150-200mg) of pancreas were suspended in Dulbecco’s phosphate buffered saline (1ml), 
using a Beadbeater (Thistle Scientific, UK), and protein lysates were prepared in RIPA buffer plus 
Complete™ protease inhibitor cocktail.  
Cell culture and experiments 
Rodent BRIN-BD11 insulinoma cells (ECACC 10033003) cells were maintained in RPMI-1640 
medium containing foetal bovine serum (10% v/v) and penicillin/streptomycin (50U/ml, 50μg/ml 
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respectively), at 37°C in a humidified atmosphere of 95% air and 5% CO2.  All experiments were 
performed in RPMI 1640 media containing 11mM glucose, unless otherwise indicated.  Transfection 
of BRIN-BD11 cells with 2g of empty vector (EV; pCMV.Neo) or the same vector encoding full 
length rodent Cyp27A1, ADX or ADXR was achieved using Amaxa Nucleofector-II (Kit V, protocol 
G010).  Stable populations were selected using G418 (400g ml-1), and cellular viability assessed by 
conversion of MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium) to 
formazan [45].  Mitochondrial membrane potential was assessed using tetramethylrhodamine ethyl 
ester (TMRE), as previously [45].  Efflux of cholesterol to apoA-I (10g ml-1), HDL (10g ml-1) and 
human serum (1%, v/v) was assessed in cells labelled with 0.5Ci ml-1 [3H]cholesterol, as described 
[41, 42, 46].  For measurement of lipid synthesis, cells were cultured in serum-free RPMI-1640 in 
the presence of [1-2 
14
C]acetate (0.5µCi/ml) [42, 46].  
Lipid Analyses 
Cellular lipids were extracted using hexane:isopropanol (3:2, v/v), as detailed [41, 42, 46] 
and  extracts dried under N2 before resuspension in isopropanol.  Lipids labelled with [
14
C]acetate 
were separated by t.l.c. using petroleum ether: diethyl ether: glacial acetic acid (90:30:1 by vol.) as 
the mobile phase.  Lipids were identified by comparison with authentic standards, and dpm 
determined by scintillation counting (Hidex 300SL).   Cholesterol mass was measured by 
colorimetric assay, as previously described [41, 42, 46].   
Protein analyses 
Protein lysates from pancreas and insulinoma cells were separated using 10% (w/v) SDS PAGE gels, 
transferred to nitrocellulose membranes, and probed using rabbit monoclonal or polyclonal 
antibodies to Cyp27A1 (1:1000), StarD1 (1:1000), TSPO (1:1000), ADX (1:1000), ADXR (1:500) 
and tubulin (1:1000) as previously [41, 42, 46], except that fluorescently-labelled secondary 
antibodies (Licor) were employed and bands quantified using a Licor Odyssey FC and Image Studio 
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software.   Mitochondria were isolated from insulinoma cell lines using a kit supplied by AbCAM 
(ab110170). 
Statistical analysis All values indicate mean±SEM; n denotes numbers of independent 
determinations.  Significant (p<0.05) differences were determined using Student’s two-way t-test 
when testing for significance between two groups of data, and one-way or repeated measures 
ANOVA and post-tests, when testing experiment with multiple outcomes, as previously [42]; 
repeated measures ANOVA was employed for paired experimental data.    
Results 
 
Pancreatic expression of mitochondrial cholesterol trafficking and metabolising proteins in obese 
(fa/fa) rats 
Expression of mitochondrial proteins involved in the transport and metabolism of cholesterol were 
examined in pancreatic tissue isolated from four month old obese Zucker (fa/fa) male rats, compared 
with lean (Fa/?) male rats.  At this age, fa/fa rats are normoglycaemic, but exhibit weight gain and 
hyperinsulinaemia, hyperlipidaemia and hepatic lipid accumulation [44] compared with lean 
controls.  Obese (fa/fa) male rats weighed significantly more than lean controls of the same age and 
gender (p<0.05), but blood glucose levels did not differ significantly between the groups (Table 1).   
Serum cholesterol and triglyceride levels were increased by 1.65-fold (p<0.01) and 2.01-fold 
(p<0.001), respectively, in obese male rats, compared with the lean controls; however, insulin was 
elevated by 17-fold (p<0.001) in obese rats, indicating a compensatory phase of increased insulin 
output in order to sustain effective glucose control (Table 1).    
Protein levels of Cyp27A1 and its redox partners ADX and ADXR in pancreatic tissue derived from 
lean and obese Zucker rats are shown in Figure 1.   Levels of Cyp27A1 protein increased by 2.4-fold 
(p=0.0002) in pancreatic tissue derived from obese rodents, compared with lean controls.   Pancreatic 
levels of ADXR protein also increased by 2.4-fold (p=0.0006) in tissue derived from obese rodents, 
compared with lean controls.  The ADXR antibody also detected a second, higher molecular weight 
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band in tissue derived from lean animals, but not from obese rodents, which remains uncharacterised, 
and was not included in the analyses performed here.  Levels of ADX did not increase significantly 
between these groups (p=0.1255). The ratio of Cyp27A1/ADXR/ADX in pancreatic tissue therefore 
changes from 1:9.3:1.6 in lean animals to 1:9.4:0.95 in obese rats.  Pancreatic levels of StAR and 
TSPO are also shown in Figure 1.   Expression of StAR protein did not change significantly in obese 
animals, compared with lean controls, but levels of TSPO increased by 2.2-fold (p=0.0004) in the 
pancreas of obese, compared with lean, rodents.  Finally, levels of LXRprotein increased by 1.8-
fold (p=0.0067) in pancreatic tissue from obese animals, compared with lean controls (Figure 1), 
suggesting increased activation of LXR [58] is associated with enhanced Cyp27A1 expression.  
Thus, altered pancreatic levels of Cyp27A1, ADXR, TSPO and LXR are triggered in response to 
genetic obesity in rodents, a condition characterised by dyslipidaemia and hyperinsulinaemia (Table 
1).   These putative relationships were explored further in rodent BRIN-BD11 insulinoma cells; 
while human pancreatic islets and -cells are known to express CYP27A1, rodent insulinoma cells 
do not, indicating that this protein is not an essential requirement for glucose-stimulated insulin 
secretion [43].  However, insulin release in BRIN-BD11 cells is responsive to modulation of 
cholesterol content [47] providing a suitable cellular context in which to examine the relationship 
between cholesterol trafficking and metabolising proteins and the cholesterol efflux pathway. 
Cholesterol efflux (2h) from wild type BRIN-BD11 cells to acceptor (apo)lipoproteins over a range 
of glucose concentrations is shown in Figure 2; human serum contains not only acceptor 
(apo)lipoproteins, but also the enzymes and transfer proteins involved in the reverse cholesterol 
transport pathway [48].  In the presence of 5mM glucose, efflux of [
3
H]cholesterol to human serum 
(1%, v/v) was significantly higher (9.5-fold; p<0.01) than that to basal media, but efflux to apoA-I 
(10g ml-1) and HDL (10g ml-1) was not significantly increased, suggesting glucose availability 
was limiting efflux.  However, in the presence of 11mM glucose, efflux was stimulated by both HDL 
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(4.8-fold; p<0.05) and human serum (9.6-fold; p<0.001), and the extent of these responses were not 
significantly altered by exposure to 20mM glucose. 
Transient introduction (48h) of full length rodent Cyp27A1 (110-fold; p=0.002; n=6) into BRIN-
BD11 cells significantly increased basal efflux (2h) of [
3
H]cholesterol (empty vector (EV; pCMV.6)  
1.95 ± 0.24% versus pCMV.6_Cyp27A1 2.60 ± 0.33%; n=6, p=0.010 in a paired two-tailed t-test).  
Stable cell populations were generated, using the same pCMV.6 vectors (Figure 3A), to achieve a 
substantial (three orders of magnitude) increase in Cyp27A1 expression in BRIN-BD11 cells 
compared with the EV control. These cell lines exhibited very similar linear growth parameters, as 
judged by the cumulative rate of conversion of MTT to formazan over a period of 0-96 h in three 
independent experiments: EV 0.55 ± 0.04 mol formazan/h (R2=0.99) versus Cyp27A1 0.59 ± 0.15 
mol formazan/h (R2=0.88), with no significant difference noted (p=0.81) between these cell 
populations.   
Protein levels of ADX, ADXR, StarD1, TSPO and LXR in Cyp27A1 overexpressing cells are also 
shown in Figure 3A.  In brief, no changes in the levels of these proteins were noted in Cyp27A1 
expressing cells, compared with EV controls; the ratio of Cyp27A1/ADXR/ADX in the former was 
1:0.184:0.109, indicating a marked excess of Cyp27A1 protein compared with its redox partners.   
Biosynthesis of free cholesterol from [
14
C]acetate (24h) did not change significantly (EV 1659.5 ± 
336.6 pmol/mg cell protein versus Cyp27A1 1405.1 ± 359.7 pmol/mg cell protein; n=6; p=0.071 in a 
two-tailed t-test) in Cyp27A1 overexpressing cells; no changes in incorporation of [
14
C]acetate into 
the cholesteryl ester pool were noted (EV 490.3 pmol/mg cell protein versus Cyp27A1 490.8 
pmol/mg cell protein; n=6).  Efflux of [
3
H]cholesterol to basal media, apoA-I, HDL or human serum 
in Cyp27A1 overexpressing cells at 2h, and at 24h, compared with the EV control is shown in Table 
2; all acceptors significantly enhanced [
3
H]cholesterol efflux above the basal condition after 24h in 
culture in both cell populations, but no significant differences between EV and Cyp27A1 
overexpressing cells were noted under any of the conditions tested.   
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The EV- and Cyp27A1-stable populations of BRIN-BD11 cells were treated with dibutyryl cAMP 
(0.3mM), to stimulate the expression and activity of StAR [31, 41], or with the TSPO ligand FGIN-
1-27 (10M) [36, 42], factors which increase mitochondrial cholesterol trafficking, LXR activation 
and/or cholesterol efflux in other cell types.  Cholesterol efflux (24h) to HDL (10g ml-1) was 
significantly increased in EV, but not Cyp27A1 cells, following preincubation with cAMP analog 
(Table 2).  Treatment with FGIN-1-27 (10M) did not significantly enhance cholesterol efflux (24h) 
to apoA-I, HDL or HS in either cell line (Table 2); further, no consistent changes in efflux of 
cholesterol to acceptors were noted following transient introduction (48h) of TSPO into Cyp27A1 
and EV cell lines (data not shown).   
By contrast, increasing the cholesterol content of EV and Cyp27A1 cell lines by preincubation with 
LDL (100g ml-1; 24h) (Figure 3B) revealed an enhanced capacity for efflux (2h) to apoA-I (1.63-
fold; p<0.01) in Cyp27A1 overexpressing cells compared with EV controls.  Efflux of cholesterol 
(2h) to human serum also increased (1.32-fold; p<0.05) in Cyp27A1 cells compared to EV, but 
removal of cholesterol by HDL remained unchanged (Figure 3C).  After 24h, efflux of 
[
3
H]cholesterol to HDL and human serum were significantly higher than basal efflux in both cell 
populations, but only basal efflux was stimulated (EV 4.35 ± 0.53 % versus Cyp27A1 6.02 ± 0.68%; 
p<0.01; n=4) by Cyp27A1 expression compared with EV controls.   
In the above experiments, expression of Cyp27A1 was markedly increased without changes in 
expression of its redox partners.   Stable cell populations were therefore generated using the same 
total amount of DNA (2g) and pCMV.6 clones expressing full length rodent Cyp27A1, ADXR and 
ADX in a 1:1:1 ratio (Figure 4A), achieving a final protein ratio of Cyp27A1/ADXR/ADX of 
1:8.36:0.52, which approximates that seen in pancreatic tissue from (fa/fa) Zucker rats (Figure 1).  
Again, these cell lines exhibited very similar linear growth parameters, as judged by the rate of 
conversion of MTT to formazan over a period of 0-96 h in three independent experiments: EV 0.75 ± 
0.07 mol formazan/h (R2=0.98) versus Cyp27A1 0.65 ± 0.06 mol formazan/h (R2=0.98), with no 
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significant difference noted (p=0.34) between these cell populations.  Altered mitochondrial 
cholesterol content was not observed in these cell lines (EV 0.225±0.063 mg cholesterol/mg protein 
versus Cyp27A1/ADXR/ADX 0.23 ± 0.055 mg cholesterol/mg protein; mean ± SEM; n=4), and no 
changes in mitochondrial membrane potential were evident (EV 23231±674 arbitrary fluorescent 
units (AFU) versus Cyp27A1/ADXR/ADX 26056 ± 2420 AFU; mean ± SEM; n=3).   
Protein levels of StarD1, TSPO and LXR in Cyp27A1/ADXR/ADX overexpressing cells are shown 
in Figure 4A.  While significant increases in Cyp27A1 (p=0.015), ADXR (p=0.019) and ADX 
(p=0.002) were noted, no alterations in StarD1, TSPO or LXR were evident.  Despite the levels of 
Cyp27A1, relative to -tubulin, being only a third of that in Figure 3A, cholesterol efflux (2h) to 
apoA-I and human serum were stimulated in Cyp27A1/ADXR/ADX cells by 1.46-fold (p<0.05) and 
1.25-fold (p<0.05) compared to EV control (Figure 4B).  At 24h, efflux to HDL and human serum 
were significantly elevated (p<0.001) above the basal condition in both cell lines, but no significant 
differences in cholesterol efflux were noted between these cell populations in three independent 
experiments (data not shown).    
The EV and Cyp27A1/ADXR/ADX stable cell lines were then exposed to cholesterol (LDL; 100g 
ml
-1
; 24h), achieving enhanced cholesterol mass (Figure 4C).  The levels of Cyp27A1, ADXR and 
ADX were measured in cholesterol loaded cells, and in the presence and absence of apoA-I (10 g 
ml
-1
; 2h).  The Cyp27A1/ADXR/ADX ratio in cholesterol-loaded cells changed from that seen in 
Figure 4A, to 1:2.75:0.59 and 1:1.31:1.45 in the absence and presence of ApoA-I, respectively, 
primarily due to a decrease in the levels of ADXR (Figure 4D).  Cholesterol efflux (2h and 24h) 
under cholesterol-loaded conditions from EV and Cyp27A1/ADXR/ADX cell lines is shown in 
Figure 4E. Efflux to apoA-I (2h) was enhanced by 1.74-fold (p<0.05) in the Cyp27A1/ADXR/ADX 
cell population, compared with the EV control, while modest increases in efflux to apoA-I and 
human were also noted in the same cell populations after 24h.  Protein levels of ABCA1 were 
measured in these cell lines under basal and cholesterol-loaded conditions (Figure 4F), in the 
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presence and absence of apoA-I (10g ml-1; 2h).  No significant differences in expression of ABCA1 
were noted in cells which were not exposed to a cholesterol load (data not shown); however, in the 
presence of apoA-I, ABCA1 levels were significantly increased (1.5-fold; p<0.05) in cholesterol-
loaded Cyp27A1/ADXR/ADX cells, compared with the equivalent EV controls.   
Overexpression of Cyp27A1 alone was sufficient to increase expression of the insulin gene (INS2) 
by nearly 4-fold (p<0.05) (Figure 5A); however, the release of insulin (30min) into media above EV 
and Cyp27A1/ADXR/ADX cell populations was stimulated by the presence of apoA-I (10g ml-1) to 
an equivalent extent (Figure 5B).  No increase in gene expression of other secretory proteins (IGF, 
VEGF) were noted in these cell lines (data not shown).  When the same cell lines were preincubated 
with LDL (100g ml-1; 24h), the release of insulin under efflux conditions (2h) was stimulated by the 
presence of apoA-I (p<0.001), HDL (p<0.001) and human serum (p<0.001), compared with the basal 
condition (Figure 5C); no insulin was detected in media from cell-free controls containing the same 
concentrations of each cholesterol acceptor.  No differences in the extent of insulin release 
stimulated by each acceptor were noted between each cell line but a significant (R
2
=0.81; p=0.002) 
relationship emerged between insulin levels in the media and cholesterol efflux (Figure 5D). Finally, 
treatment with 0.8mM octanol (2h) was used to mobilise the plasma membrane cholesterol pool [49, 
50] in both stable cell populations, and insulin release measured in the presence of apoA-I.  
Compared with the vehicle control (ethanol, 0.1%, v/v), treatment with octanol significantly 
decreased insulin release in EV cells (19.72 ± 3.72 ng insulin mg
-1
 cell protein versus octanol 11.23 
± 3.58 ng insulin mg
-1
 cell protein; n=3; p<0.01), but not in the Cyp27A1/ADXR/ADX cell 
population (16.4 ng insulin mg
-1
 cell protein versus octanol 11.55 ± 2.94 ng insulin mg
-1
 cell protein; 
n=3).   
Discussion 
The present study demonstrates that hyperinsulinaemia and hyperlipidaemia in normoglycaemic 
genetically obese male rodents is accompanied by increased protein expression of Cyp27A1, ADXR 
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and TSPO, and nuclear transcription factor LXR in pancreatic tissue.  The relationships between 
changes in expression of these mitochondrial cholesterol trafficking and metabolising proteins, and 
the cholesterol efflux pathway, were then probed in rodent BRIN-BD11 insulinoma cells.  
Reconstitution of Cyp27A1 in BRIN-BD11 cells, which do not express this enzyme (unlike human 
-cells) [43], increased the expression of INS2, without affecting lipid metabolism, in the absence of 
a cholesterol ‘load’.  However, after exposure to LDL, enhanced cholesterol efflux to apoA-I and 
human serum were noted in Cyp27A1 expressing cells, compared with controls.  Agents that bind 
and/or activate StAR and TSPO did not markedly impact cholesterol efflux, either in the presence or 
absence of Cyp27A1.  Co-transfection of Cyp27A1, ADX and ADXR, in a ratio approximating that 
in obese pancreatic tissue, stimulated ABCA1-dependent cholesterol efflux to apoA-I in both basal 
and cholesterol-loaded cells, compared with controls.  Insulin release into the media was stimulated 
by all acceptors to a similar extent, but proved more susceptible to mobilisation of plasma membrane 
cholesterol in control cells than in cells expressing Cyp27A1 and its redox partners.   
Obesity has previously been linked to altered expression of Cyp27A1 in mice, in a tissue-specific 
manner: in male C57BL/6 mice fed a high fat diet, hepatic expression of Cyp27A1 were found to be 
lower than in control mice, while the reverse was true in visceral adipose tissue, and has been 
associated with changes in vitamin D metabolism [51].  While pancreatic expression of Cyp27A1 
has not previously been investigated, 27-hydroxycholesterol is a major product of cholesterol 
metabolism in adipocytes, and inhibition of Cyp27A1 activity or knockdown/deletion of Cyp27A1 
induces adipocyte differentiation [52, 53]. It is possible that induction of Cyp27A1 may therefore be 
an autocrine or paracrine response to limit adipocyte hyperplasia during overfeeding, and could exert 
a similarly protective function in pancreatic tissue to prevent cholesterol accumulation in genetic 
obesity [52, 53].  Loss of Cyp27A1 activity has also been linked to increased concentrations of active 
glucocorticoids [54], so one hypothesis could be that pancreatic induction of Cyp27A1 expression, 
possibly mediated by activation of glucocorticoid receptors [55, 56], could help to reduce the impact 
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of increased circulating concentrations of these stress hormones in obesity [57].  Alternatively, 
pancreatic induction of Cyp27A1 may contribute to the compensatory response leading to 
hyperinsulinaemia in fa/fa Zucker rats.  We hypothesize that increased local (auto/paracrine) 
production of endogenous oxysterol ligands for Liver X receptors [58], which diffuse within tissues 
and the bloodstream, may explain increased pancreatic expression of LXRE-dependent Liver X 
receptors observed in obese rodents.   
Regulation of ADX and ADXR expression has not previously been studied in pancreatic tissue, or 
the context of genetic obesity.  However, the availability of ADXR and ADX can limit the activity of 
CYP11A1 [59, 60], while co-transfection of both redox partners achieves the reverse [32, 61] so that 
the altered ratio of Cyp27A1/ADXR/ADX in pancreatic tissue from obese rats may alter the 
efficiency of this cholesterol metabolising complex.  By contrast, TSPO is repressed by obesity in 
white and brown adipose tissue [62], but up-regulated in the brain following administration of a high 
fat obesogenic diet [63], and TSPO ligands have been linked with improved metabolic and/or 
inflammatory status in a number of chronic disease states [52, 53, 64].  The increase in pancreatic 
expression of TSPO noted here, therefore, could impact on the cholesterol efflux pathway [42] or 
exert a number of other protective effects sustaining pancreatic function under the challenge of 
genetic obesity, which could be explored in future studies.   
The causal relationships between these proteins and the cholesterol efflux pathway mediated by 
ABCA1, which can help to sustain -cell function [19-21, 65], were evaluated in BRIN-BD11 
insulinoma cells.  In interpreting these data, it is important to recognise the distinctions between 
BRIN-BD11 cells and primary -cells: electrofusion of rat pancreatic -cells with immortal RINm5F 
cells created glucose- and amino acid-responsive clonal insulin-secreting BRIN-BD11 cells [66, 67] 
which are highly proliferative in culture, unlike adult human -cells [8].  Wild type BRIN-BD11 
cells exhibited glucose-dependent efflux of [
3
H]cholesterol to HDL and human serum, but efflux to 
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apoA-I was not significantly higher than the basal condition, indicating a low capacity for production 
of nascent HDL via ABCA1. 
Overexpression of Cyp27A1 in BRIN-BD11 cells did not affect the biosynthesis, esterification or 
efflux of cholesterol under basal conditions but enhanced efflux to ApoA-I and human serum in cells 
previously exposed to native LDL.  These findings resonate with our previous study, which 
suggested that rapidly proliferating BRIN-BD11 cells have sub-optimal levels of cholesterol [47], 
and with that of Fu et al [24], who demonstrated enhanced induction of LXR-dependent genes 
involved in the cholesterol efflux pathway in cholesterol-loaded Cyp27-expressing cells, compared 
with controls. However, ligation of TSPO, using FGIN-1-27, had no impact on the cholesterol efflux 
pathway in stable populations of Cyp27A1 or EV BRIN-BD11 cells.  This finding differs from our 
studies in macrophages [42] and in retinal pigment epithelium cells [68] which demonstrated that this 
compound enhances cholesterol efflux to apoA-I, apoE and HDL, an effect which was amplified in 
cells overexpressing TSPO, and lost after knockdown or genetic ablation of this protein.  Equally, the 
addition of a cAMP analog to stimulate the expression and activity of StAR, did not stimulate the 
efflux pathway in either cell line, despite the reported impact of this protein on this pathway, and on 
lipid metabolism, in macrophages [39-42] and hepatocytes [29, 30, 46].   This suggests that the 
mitochondrial cholesterol trafficking complex does not have a major role to play in BRIN-BD11 
cells, which do not normally express Cyp27A1; the oxysterols required for ligation of LXRs may 
therefore derive from the cholesterol biosynthetic pathway rather than from mitochondrial 
metabolism of excess cholesterol [69].  This may also explain the low capacity for generation of 
nascent HDL from apoA-I in the absence of a cholesterol ‘load’ observed.    
Intriguingly, however, Cyp27A1-expressing BRIN-BD11 cells expressed higher levels of INS2 than 
EV controls, even under basal conditions, an outcome consistent with the reported increases in 
nuclear Pdx-1, and enhanced Pdx-1 binding to the insulin promoter, after treatment of human islets 
with LXR agonist, T0901317 [70]. Thus, the expression of INS2 may be more sensitive to 
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inCyp27A1 induced changes in oxysterol ‘tone’ than the pathway governing cholesterol removal 
from these cells.    Further, metabolism of oxysterols to more polar products, including bile acids, 
has been described in macrophages [71]; bile acids are increasingly recognised as signalling 
molecules with metabolic and endocrine functions [72].  While bile acids have no direct effect on 
insulin secretion from perfused pancreas [73], it is a limitation of this study that these products were 
not identified and their physiological impact characterised in the BRIN-BD11 cell lines.   
While overexpression of Cyp27A1 alone was sufficient to enhance efflux to apoA-I in macrophages 
and Chinese Hamster Ovary cells [24, 74-76], and to reduce hepatic inflammation in LDL receptor
-/-
 
mice [77], it is clear that optimal processing of cholesterol and cholesterol metabolites in other cell 
types, and in BRIN-BD11 cells, requires co-transfection with its redox partners ADX and ADXR 
[32, 59-61, 77].  Interestingly, after exposure to native LDL, the level of ADXR declined, relative to 
-tubulin, suggesting either a loss of endogenous ADXR expression and/or post-translational 
degradation of this protein.    Despite this, efflux to apoA-I and human serum remained enhanced, 
reflected in increased expression of ABCA1 protein.   Importantly, we did not observe changes in 
mitochondrial membrane potential or accumulation of mitochondrial cholesterol after overexpression 
of Cyp27A1/ADXR/ADX.  The former finding supports the concept that it is the conversion of 
cholesterol to oxysterol which is important in modulating the cholesterol efflux pathway in this cell 
type, rather than the rate of cholesterol delivery to mitochondria, which is known to be modulated by 
m in macrophages [78, 79] and steroidogenic cells [80].  Thus, in BRIN-BD11 cells, Cyp27A1 
appears more effective in stimulating the ABCA1-dependent cholesterol efflux pathway when co-
transfected with its redox partners, than when expressed at much higher levels alone, and this effect 
is also evident following increased flux of LDL cholesterol via the endocytic pathway.   
Insulin release into the culture media was increased by the presence of apoA-I, HDL and human 
serum, with a positive correlation emerging between efflux capacity and insulin release.  However, 
no impact of Cyp27A1/ADXR/ADX overexpression on insulin release, compared to the EV control, 
18 
 
could be detected: we speculate that intracellular accumulation of much higher (pathological) levels 
of cholesterol, or exposure to oxidatively modified forms of LDL, may be required for the full 
protective effect of this pathway to be manifest.   Certainly, insulin granules are the major sites of 
intracellular cholesterol accumulation in -cells, and delivery of excess cholesterol to insulin 
granules can cause defects in their locale, maturation and docking at the plasma membrane [81].   
In summary, genetic obesity is associated with hyperinsulinaemia, dyslipidaemia and increased 
pancreatic expression of Cyp27A1, ADXR, TSPO, and LXR, while overexpression of Cyp27A1 
and/or its redox partners promotes the expression of ABCA1 and enhances cholesterol efflux from 
insulin-secreting cells to apoA-I and HDL.   These cellular responses should help to guard against 
the accumulation of excess intracellular cholesterol which can cause impaired insulin secretion [11-
14], particularly since ABCA1 is required for exocytosis of insulin secretory granules [19-21], and 
beta-cell function is sustained by the multiple protective properties of HDL [2-4; 8-10].   The ability 
to induce the Cyp27A1 pathway may therefore be an important protective mechanism, particularly in 
‘pre-diabetic’ individuals characterised by low levels of dysfunctional HDL, in whom insulin 
resistance requires a compensatory phase of hyperinsulinaemia to maintain normoglycaemia [82].  
Once pancreatic -cells can no longer compensate for insulin resistance, full-blown T2DM with 
hyperglycaemia develops: it is estimated that one in three adults in England are on this threshold, 
which may last for up to ten years [83].  Further work is required to establish the therapeutic 
potential of the Cyp27A1 pathway in sustaining beta cell capacity during this period.          
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Table 1 Weight, serum glucose, cholesterol, triglyceride and insulin levels in 4 month old 
male obese Zucker (fa/fa) and lean (Fa/?) rats 
 
 Lean male rats Obese male rats Significance 
Weight (g) 441.1±10.7  (n=9) 550.4±31.2 (n=5) p=0.029 
Serum glucose (mM) 8.01±0.25 (n=9) 11.16 ±1.98 (n=5) p=0.190 
Serum cholesterol (mM) 3.94±0.08 (n=9) 6.53±0.31 (n=5) p=0.0013 
Serum triglyceride (mM) 1.56±0.08 (n=9) 3.14±0.19 (n=5) p=0.0006 
Serum insulin (ng/ml) 6.05±0.71 (n=9) 103.2±11.29 (n=5) p=0.0010 
 











Table 2 The effect of overexpression of Cyp27A1 on [
3






















Basal 0.64 ± 0.12 % 
(n=3) 
0.96 ± 0.32 %  
(n=3) 
6.44 ± 0.23 % 
(n=15) 




1.76 ± 0.32 % 
(n=3) 
1.91 ± 0.34 %  
(n=3) 
8.76 ± 0.40 %*** 
(n=15) 




2.39 ± 0.24 % * 
(n=3) 
2.47 ± 0.28 % 
* (n=3) 
14.62 ± 1.10 % 
*** (n=11) 




3.84 ± 0.36 % 
*** (n=3) 
4.07 ± 0.61 % 
*** (n=3) 
23.34 ± 0.57 % 
*** (n=11) 




- - 7.09 ± 0.55 % 
(n=3) 






- - 9.69 ± 0.77 % 
(n=3) 





- - 16.57 ± 0.52 % 
†(n=3) 






- - 24.13 ± 0.31 % 
(n=3) 






- 7.53 ± 0.89 % 
(n=3) 






- - 8.13 ± 0.51 % 
(n=3) 





(10 g ml-1) 
- - 15.02 ± 1.03 % 
(n=3) 






- - 23.85 ± 0.60 % 
(n=3) 
23.97 ± 0.89 % 
(n=3) 
 
Values are the mean ± SEM for the number of independent experiments indicated by ‘n’; each 
independent experiment was performed using triplicate wells of cultured cells.  Significant 
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differences in efflux due to each acceptor from basal (EV) and basal (Cyp27A1) controls are 
indicated: *p<0.05; ***p<0.001.  No differences in efflux were noted between EV and Cyp27A1 
stable cell populations under any of the conditions tested.  The significant difference in efflux to 
HDL, due to the presence of dibutyryl cAMP (0.3mM; 24h) in the EV stable population of cells, is 
indicated †p<0.05.   No significant differences in efflux were found due to treatment with FGIN-1-27 
(10 M; 24h) in paired experiments from EV or Cyp27A1 stable populations of cells.    
Figure Legends 
Figure 1 
Pancreatic levels of Cyp27A1, ADXR, ADX, StAR, TSPO and LXR relative to -tubulin, in total 
pancreatic tissue extracted from lean (Fa/?; n=6) and obese (fa/fa; n=5) male rats measured by 
Western blotting. Values are mean±SEM; **p<0.01, ***p<0.001 compared with lean controls. 
Figure 2 
Efflux (2h) of [
3
H]cholesterol to media (basal), apoA-I (10g ml-1), HDL (10g ml-1) and human 
serum (1%, v/v) from wild type BRIN-BD11 insulinoma cells, in the presence of RPMI 1640 media 
containing 5mM (n=3), 11mM (n=6) or 20mM (n=3) glucose.  Values are mean ± SEM; *p<0.05, 
**p<0.01 and ***p<0.001 compared with the basal control under the equivalent glucose 
concentration.   
Figure 3 
Representative Western blot images and levels of Cyp27A1, ADXR, ADX, StAR, TSPO and LXR, 
relative to -tubulin, in stable populations of BRIN-BD11 cells transfected with Cyp27A1, or the 
empty vector (EV) control are shown in 3A.  Values are mean ± SEM of between three and five 
independent experiments; *p<0.05 compared with the EV control.  The total cholesterol mass in EV 
and Cyp27A1 expressing cell populations under basal conditions, and following exposure to native 
LDL (100g ml-1; 24h) is shown in Figure 3B.  Values are mean ± SEM, n=4; *p<0.05 for the 
comparisons indicated.  Efflux of [
3
H]cholesterol from Cyp27A1 and EV cell populations, after 
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exposure to native LDL (100g ml-1; 24h), to basal media, apoA-I (10g ml-1), HDL (10g ml-1) and 
human serum (1%, v/v), after 2h and 24h, are shown in Figure 3C.  Values are mean ± SEM, n=4; 
*p<0.05 for the comparisons indicated.   
Figure 4 
Representative Western blot images and levels of Cyp27A1, ADXR, ADX, StAR, TSPO and LXR, 
relative to -tubulin, in stable populations of BRIN-BD11 cells transfected with 
Cyp27A1/ADX/ADXR, or the empty vector (EV) control are shown in 4A.  Values are mean±SEM 
of seven independent experiments; *p<0.05, **p<0.01 compared with the EV control.  Efflux of 
[
3
H]cholesterol to basal media, apoA-I (10g ml-1), HDL (10g ml-1) and human serum (1%, v/v), 
after 2h is shown in 4B (mean±SEM; n=4);  *p<0.05 and **p<0.0.01 for the comparisons indicated.  
The total cholesterol mass in EV and Cyp27A1/ADXR/ADX expressing stable cell populations 
under basal conditions, and following exposure to native LDL (100g ml-1; 24h) is shown in Figure 
4C.  Values are mean ± SEM, n=3; *p<0.05 for the comparisons indicated.  Representative Western 
blot images and protein levels of Cyp27A1, ADXR and ADX in these stable cell populations, after 
exposure to native LDL (100g ml-1; 24h), and in the presence and absence of apoA-I (10g ml-1; 
2h) are shown in Figure 4D.  Values are mean ± SEM, n=3; *p<0.05 compared to the EV control.  
Efflux of [
3
H]cholesterol from Cyp27A1/ADXR/ADX and EV cell populations, after exposure to 
native LDL (100g ml-1; 24h), to basal media, apoA-I (10g ml-1), HDL (10g ml-1) and human 
serum (1%, v/v), after 2h (n=6) and 24h (n=5), are shown in Figures 4E.  Values are mean±SEM, n= 
3; *p<0.05, ***p<0.001 for the comparisons indicated.  Levels of ABCA1 protein, in EV and 
Cyp27A1/ADXR/ADX cell lines, after exposure to native LDL (100g ml-1), in the presence and 
absence of apoA-I (10g ml-1; 2h) are shown in Figure 4F.  Values are mean±SEM, n=4; *p<0.05 




The expression of the INS2 gene, relative to -tubulin, in EV and Cyp27A1 expressing stable 
populations is shown in Figure 5A; values are mean±SEM, n=6; *p<0.05 compared with the EV 
control.  Release of insulin (30 min) into the media above EV and Cyp27A1/ADXR/ADX cells, in 
response to apoA-I (10 mg ml-1) is shown in Figure 5B; values are mean ± SEM, n=3; *p<0.05, 
**p<0.01 for the comparisons indicated.  Release of insulin under efflux conditions (2h) into basal 
media, or media supplemented with apoA-I (10g ml-1), HDL (10g ml-1) and human serum (1%, 
v/v) following incubation in the presence of native LDL (100g ml-1, 24h), is shown in Figure 5C, 
with the correlation between insulin release and % efflux shown in Figure 5D.  Values are 
mean±SEM, n=5; ***p<0.001 compared with the relevant basal control.  
 
 
 
 
